What other research is promising, and where do you expect myeloma research to be in 5 years?Chapter 1
In this segment, Dr Lesokhin discusses new and emerging classes of drugs likely to transform treatment for patients with myeloma.
PD-1 inhibition is noted as very promising for myeloma, though clinical trials haven’t shown a promising ORR. Why do you think this is?
In this segment, Dr Lesokhin discusses the potential of checkpoint inhibition for multiple myeloma.
Can anything be done to mitigate the toxicity of PD-1/PD-L1 inhibition in myeloma?
In this segment, Dr Lesokhin discusses the management of toxicity related to PD-1 blockade in myeloma, including the possibility of re-challenge.
What potential does CAR-T cell therapy have in myeloma?
In this segment, Dr Lesokhin discusses how CAR-T cell therapy may be used in patients with multiple myeloma.